The CEO of Novo Nordisk is looking to expand the company's focus beyond weight loss to areas such as longevity and aesthetics. This shift in focus may be related to the company's existing products, including a type two diabetes treatment that has shown success in weight loss. The company's stock price has dropped, possibly in response to the CEO's comments on future growth drivers.